AngioDynamics, Inc. (ANGO)

In October 2025, AngioDynamics reported a 12.2% increase in net sales and a 26.1% increase in Med Tech net sales for its fiscal year 2026 first-quarter financial results. In November 2025, the company participated in the UBS Global Healthcare Conference. In January 2026, AngioDynamics announced an 8.8% increase in net sales and a 13.0% increase in Med Tech net sales for its fiscal year 2026 second-quarter financial results, achieved three regulatory milestones for its Mechanical Thrombectomy portfolio, and announced the retirement of CEO Jim Clemmer. In February 2026, AngioDynamics expanded indications for its NanoKnife System across Europe and launched an investigator-led research fund with The PERT Consortium® to advance pulmonary embolism care. In March 2026, AngioDynamics presented at the Leerink Partners Global Healthcare Conference. In April 2026, the company reported an 8.9% increase in net sales for its fiscal year 2026 third-quarter financial results, driven by a 19.0% growth in Med Tech revenue, and raised its full-year FY2026 guidance for net sales and Adjusted EBITDA.

The provided information does not explicitly detail any specific demand seasonality for AngioDynamics, Inc.'s products and services.

AngioDynamics, Inc. is a medical technology company focused on designing, manufacturing, and selling medical, surgical, and diagnostic devices, particularly for minimally invasive procedures in peripheral vascular disease, oncology, and surgical settings. The company operates in the Health Technology sector, with its product portfolio divided into Med Tech (high-growth platforms like Auryon, NanoKnife, AngioVac, and AlphaVac) and Med Device (core, venous, ports, oncology, vascular access, angiographic, drainage, thrombolytic, and venous products).

AngioDynamics has a global presence across North America, Europe, and Asia, with the United States being its largest market, accounting for approximately 72% of its FY2024 net sales, and Europe representing about 22%. The company has facilities in New York and Massachusetts in the U.S., and operations in Canada, Hong Kong, the Netherlands, Israel, and Brazil, utilizing both direct sales forces and distribution partners.

AngioDynamics is known as a leading provider of innovative medical devices for minimally invasive procedures. The company's commitment to advancing medical solutions and its focus on high-growth areas contribute to its positive standing. Recent regulatory clearances and consistent double-digit growth in its Med Tech segment reflect positively on its brand and product acceptance. No specific events negatively impacted AngioDynamics' brand reputation in the past year.

AngioDynamics' ownership is primarily held by institutional investors, who manage approximately 89.43% of the company's outstanding shares. Major institutional shareholders include BlackRock, Inc., Point72 Asset Management, L.P., Systematic Financial Management Lp, The Vanguard Group, Inc., Kotler Kevin, Armistice Capital, Llc, Weber Capital Management Llc /adv, Nuveen, LLC, State Street Corp, and Royce & Associates Lp. Individual investors account for about 17% of the ownership, and insiders hold approximately 5.36% of the company's stock.